BRCA1 and breast carcinoma: A clinical study using PARP inhibitors, such as Olaparib and BSI-201, is now ongoing and shows clinical efficacy in the treatment of BRCA1/2-related breast, ovarian, and prostate cancers, as well as sporadic basal-like breast cancers [71].